Tema Heart & Health ETF (NASDAQ:HRTS) Stock Short Interest Report for September

Tema Heart & Health ETF (NASDAQ:HRTS) was the recipient of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totaling 520 shares, a decrease of 43.3% from the September 15th total of 917 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily volume of 1,835 shares, the short-interest ratio is currently 0.3 days.

Tema Heart & Health ETF Trading Down 0.9%

NASDAQ HRTS traded down $0.32 during trading on Friday, hitting $36.91. 2,360 shares of the company’s stock were exchanged, compared to its average volume of 5,306. The company has a market cap of $54.62 million, a PE ratio of 22.06 and a beta of 0.65. Tema Heart & Health ETF has a fifty-two week low of $31.95 and a fifty-two week high of $38.87. The stock’s 50 day moving average price is $36.95 and its two-hundred day moving average price is $35.58.

Hedge Funds Weigh In On Tema Heart & Health ETF

Hedge funds have recently made changes to their positions in the stock. Rothschild Capital Partners LLC bought a new stake in Tema Heart & Health ETF during the second quarter valued at $651,000. Royal Bank of Canada raised its position in shares of Tema Heart & Health ETF by 8.8% in the 1st quarter. Royal Bank of Canada now owns 21,083 shares of the company’s stock worth $710,000 after acquiring an additional 1,703 shares in the last quarter. Members Advisory Group LLC acquired a new position in shares of Tema Heart & Health ETF in the 2nd quarter valued at about $398,000. Anson Capital Inc. acquired a new position in shares of Tema Heart & Health ETF in the 2nd quarter valued at about $297,000. Finally, XML Financial LLC bought a new stake in shares of Tema Heart & Health ETF during the 2nd quarter valued at about $223,000.

Tema Heart & Health ETF Company Profile

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.